{"nctId":"NCT01661946","briefTitle":"Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye","startDateStruct":{"date":"2012-08"},"conditions":["Diabetic Macular Edema"],"count":10,"armGroups":[{"label":"Ranibizumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab"]},{"label":"Bevacizumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab"]}],"interventions":[{"name":"Bevacizumab","otherNames":["Avastin"]},{"name":"Ranibizumab","otherNames":["Lucentis"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients in whom anti-vascular endothelial growth factor (VEGF) therapy is indicated for the treatment of diabetic macular edema\n* able to return for extra clinic visits according to study schedule\n\nExclusion Criteria:\n\n* active malignancy\n* previous retinal laser treatment\n* previous anti-VEGF therapy\n* previous vitrectomy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Concentration (Cmax) of Anti-VEGF Antibody","description":"The serum concentrations of anti-VEGF antibody (bevacizumab or ranibizumab) will be measured pre-injection as well as at various time points after injection (1 day, 1 week, 2 weeks, 1 month). These time points are selected based on previously completed animal studies. The Cmax will be compared between bevacizumab and ranibizumab.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.22","spread":"7.59"},{"groupId":"OG001","value":"9.56","spread":"2.50"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":[]}}}